Skip to content
All Sections
Subscribe Now
68°F
Tuesday, October 1st 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
68°F
Tuesday, October 1st 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
DMV scraps test for some
Man hit, killed by fire engine
Disney price bump to come?
Affordable senior housing opens
High School Football
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaccitech Plc ADR
(NQ:
VACC
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
4.950 (1)
Ask (Size)
5.180 (5)
Prev. Close
5.000
Today's Range
N/A - N/A
52wk Range
3.000 - 4.540
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
November 06, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 31, 2023
Via
Benzinga
Performance
More News
Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
October 09, 2023
Via
InvestorPlace
Analyst Expectations for Vaccitech's Future
June 13, 2023
Via
Benzinga
Vaccitech: Q1 Earnings Insights
May 12, 2023
Via
Benzinga
Vaccitech Earnings Perspective: Return On Capital Employed
March 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 26, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 26, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
September 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
September 25, 2023
Via
Benzinga
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
September 26, 2023
Via
FinancialNewsMedia
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
September 13, 2023
From
Vaccitech plc
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
September 11, 2023
Via
Benzinga
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
August 10, 2023
From
Vaccitech plc
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
September 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 04, 2023
Via
Benzinga
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
June 21, 2023
From
Vaccitech plc
Via
GlobeNewswire
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
June 12, 2023
From
Vaccitech plc
Via
GlobeNewswire
Over $4M Bet On Diversified Healthcare Trust? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
June 02, 2023
Via
Benzinga
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
April 17, 2023
From
Vaccitech plc
Via
GlobeNewswire
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
April 05, 2023
Via
InvestorPlace
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
March 28, 2023
From
Vaccitech plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
March 24, 2023
Via
Benzinga
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 24, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close